Shots: FDA approves Kyowa Kirin’s Poteligeo drug for R/R Mycosis fungoides (MF) and Sézary syndrome (SS) Poteligeo received Orphan Drug designation with addition permission granted on basis of Priority Review and Breakthrough Therapy The approval is based on a clinical trial of 372 patients with MF or SS. Study reported mPFS (Poteligeo vs Vorinostat) is […]Read More
Tags : Two Rare
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US